AUG 19, 2020 3:08 PM PDT

Cancer Mutation Improves Chemo Drug Performance

WRITTEN BY: Tara Fernandez

 

When it comes to cancer biomarkers, it’s often the genetic signatures that are associated with poor patient outcomes that take center stage. Take for example triple-negative breast cancer, a diagnostic marker for a condition that is notoriously difficult to treat and puts patients at significantly higher risks of relapse after therapy.

A team of cancer researchers based at the Terry Fox Research Institute have identified a gene mutation in lymphoma that serves as a biomarker for the opposite — it’s associated with improved patient survival instead.

Scientists David Scott and Christian Steidl led the study which was published in Nature Medicine. Here, they describe that patients with Diffuse Large B-cell Lymphoma, or DLBCL that lack a particular protein called TMEM30A are actually more susceptible to chemotherapeutic drugs, leading to better outcomes.

Shannon Healy, the first author of the paper said, “In contrast to most studies that describe gene mutations associated with poor survival, we observed that DLBCL cells with complete loss of TMEM30A actually showed increased uptake of cytotoxic drugs, most notably those that are used to treat DLBCL, such as doxorubicin and vincristine.”

DLBCL is the most common type of non-Hodgkin lymphoma worldwide. In the United States, almost 20,000 people are diagnosed with this aggressive cancer annually. It affects a particular subset of immune cells called B-lymphocytes which produce antibodies to resist infections.

The team’s discovery sheds light on why some cancer patients respond much more favorably to cytotoxic drugs than others. In the case of DLBCL, the research team believes that the TMEM30A mutation allows these cancer-killing drugs to pass through the cell membrane more efficiently. This could translate to a new generation of future therapeutics that target TMEM30A to shuttle the cytotoxic molecules into cancer cells.

 


Sources: Nature Medicine, The Terry Fox Research Institute.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUN 16, 2021
Cell & Molecular Biology
A Potential Way to Prevent Metastatic Cancer
JUN 16, 2021
A Potential Way to Prevent Metastatic Cancer
Metastatic cancer is the deadliest, and it can happen years after cancer has been treated to the point of remission. Met ...
JUL 20, 2021
Coronavirus
Pregnant and lactating people can pass COVID-19 antibodies from the vaccine
JUL 20, 2021
Pregnant and lactating people can pass COVID-19 antibodies from the vaccine
New research found that both pregnant and lactating people who receive the COVID-19 vaccine can pass antibodies to their ...
AUG 12, 2021
Health & Medicine
Why Autoimmune Diseases Strike Women More Often Than Men
AUG 12, 2021
Why Autoimmune Diseases Strike Women More Often Than Men
According to a 2020 study published in Cureus, autoimmune diseases are two times more prevalent in women than men, with ...
AUG 19, 2021
Immunology
Insights Into the Interplay Between COVID and the Nasal Microbiome
AUG 19, 2021
Insights Into the Interplay Between COVID and the Nasal Microbiome
There is a spectrum of COVID symptom severity: some recover after experiencing nothing more than a mild cough, while oth ...
AUG 27, 2021
Health & Medicine
Blood Group and COVID-19 Susceptibility- An Ongoing Debate
AUG 27, 2021
Blood Group and COVID-19 Susceptibility- An Ongoing Debate
Since their discovery, there has been an interest in how ABO blood groups and infectious diseases may be related. In add ...
SEP 13, 2021
Microbiology
Flu Season Looms Large as World May Have an 'Immunity Debt'
SEP 13, 2021
Flu Season Looms Large as World May Have an 'Immunity Debt'
Scientists are beginning to speculate about the possibility that the flu season this year will be particularly bad becau ...
Loading Comments...